Encouraging first results with Altropane:
This article was originally published in Clinica
Executive Summary
Promising results have been achieved in initial trials of Boston Life Sciences' Altropane with three healthy patients. The agent could be an accurate means of imaging the brain dopamine transporter system within one hour of injection, says Dr Marc Lanser, chief scientific officer of Boston Life Sciences (US). It is hoped that it will permit a precise, noninvasive diagnosis of Parkinson's disease (see Clinica 675, p 19).